BibTex format
@article{Moshe:2021,
author = {Moshe, M and Daunt, A and Flower, B and Simmons, B and Brown, JC and Frise, R and Penn, R and Kugathasan, R and Petersen, C and Stockmann, H and Ashby, D and Riley, S and Atchison, C and Taylor, GP and Satkunarajah, S and Naar, L and Klaber, R and Badhan, A and Rosadas, C and Marchesin, F and Fernandez, N and Sureda-Vives, M and Cheeseman, H and O'Hara, J and Shattock, R and Fontana, G and Pallett, SJC and Rayment, M and Jones, R and Moore, LSP and Ashrafian, H and Cherapanov, P and Tedder, R and McClure, M and Ward, H and Darzi, A and Cooke, GS and Barclay, WS and On, behalf of the REACT Study team},
journal = {BMJ: British Medical Journal},
pages = {1--8},
title = {SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study},
url = {https://www.bmj.com/content/372/bmj.n423},
volume = {372},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Objective: To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national COVID-19 seroprevalence programme (REACT2).Design: Laboratory sensitivity and specificity analyses were performed for seven LFIAs on a minimum of 200 sera from individuals with confirmed SARS-CoV-2 infection, and 500 pre-pandemic sera respectively. Three LFIAs were found to have a laboratory sensitivity superior to the finger-prick sensitivity of the LFIA currently used in REACT2 seroprevalence studies (84%). These LFIAs were then further evaluated through finger-prick testing on participants with confirmed previous SARS-CoV-2 infection. Two LFIAs (Surescreen, Panbio) were evaluated in clinics in June-July, 2020, and a third LFIA (AbC-19) in September, 2020. A Spike protein enzyme-linked immunoassay (S-ELISA) and hybrid double antigen binding assay (DABA) were used as laboratory reference standards.Setting: Laboratory analyses were performed at Imperial College, London and University facilities in London, UK. Research clinics for finger-prick sampling were run in two affiliated NHS trusts.Participants: Sensitivity analysis on sera were performed on 320 stored samples from previous participants in the REACT2 programme with confirmed previous SARS-CoV-2 infection. Specificity analysis was performed using 1000 pre-pandemic sera. 100 new participants with confirmed previous SARS-CoV-2 infection attended study clinics for finger-prick testing.Main outcome measures: The accuracy of LFIAs in detecting IgG antibodies to SARS-CoV-2 in comparison to two in-house ELISAs.Results: The sensitivity of seven new LFIAs using sera varied between 69% and 100% (vs S-ELISA/hybrid DABA). Specificity using sera varied between 99.6% and 100%. Sensitivity on finger-prick testing for Panbio, Surescreen and AbC-19 was 77% (CI 61.4 to 88.2), 86% (CI 72.7 to 94.8) and 69% (CI 53.8 to 81.3) respectively vs S-ELISA/hybrid DABA. Sensitivity for sera from matched clinical samples performe
AU - Moshe,M
AU - Daunt,A
AU - Flower,B
AU - Simmons,B
AU - Brown,JC
AU - Frise,R
AU - Penn,R
AU - Kugathasan,R
AU - Petersen,C
AU - Stockmann,H
AU - Ashby,D
AU - Riley,S
AU - Atchison,C
AU - Taylor,GP
AU - Satkunarajah,S
AU - Naar,L
AU - Klaber,R
AU - Badhan,A
AU - Rosadas,C
AU - Marchesin,F
AU - Fernandez,N
AU - Sureda-Vives,M
AU - Cheeseman,H
AU - O'Hara,J
AU - Shattock,R
AU - Fontana,G
AU - Pallett,SJC
AU - Rayment,M
AU - Jones,R
AU - Moore,LSP
AU - Ashrafian,H
AU - Cherapanov,P
AU - Tedder,R
AU - McClure,M
AU - Ward,H
AU - Darzi,A
AU - Cooke,GS
AU - Barclay,WS
AU - On,behalf of the REACT Study team
EP - 8
PY - 2021///
SN - 0959-535X
SP - 1
TI - SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study
T2 - BMJ: British Medical Journal
UR - https://www.bmj.com/content/372/bmj.n423
UR - http://hdl.handle.net/10044/1/86108
VL - 372
ER -